FLI-06

Research use only, not for human use.

FLI-06 is a Notch signaling inhibitor (EC50: 2.3 μM).

FLI-06 is a Notch inhibitor and the early secretory pathway inhibitor. FLI-06 disrupts the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibits general secretion at a step before exit from the endoplasmic reticulum (ER), which was accompanied by a tubule-to-sheet morphological transition of the ER. FLI-06 is the first small molecule acting at such an early stage in secretory traffic. Notch signaling has a pivotal role in numerous cell-fate decisions, and its aberrant activity leads to developmental disorders and cancer.

FLI-06, disrupted the Golgi apparatus in a manner distinct from that of brefeldin A and golgicide A. FLI-06 inhibited general secretion at a step before exit from the endoplasmic reticulum. In FLI-06–treated cells, no APPCTF accumulates despite strongly reduced Aβ secretion, suggesting that it acts upstream of α-secretase and β-secretase cleavage. FLI-06 is a very useful chemical probe to study the inhibition of membrane traffic at pre- ER-exit site (ERES) stages without fusion of ER-Golgi.

——

FLI06 | FLI 06 | FLI06

Chromatin/Epigenetic

Epigenetic Reader Domain

Notch

Cancer

——

313967-18-9

438.52

C25H30N2O5

>98% (HPLC)

DMSO : ≥ 38 mg/mL; 86.66 mM

CC1=C(C(c2ccc(cc2)[N+](=O)[O-])C2=C(CC(C)(C)CC2=O)N1)C(=O)OC1CCCCC1

cyclohexyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate

(-20℃)

With Ice Pack

≥ 2 years